SBIR/STTR Research Award

Detecting species-specific bacterial meningitis markers with iDDS probes

Award identifier 2fb659e5d9b8532c207d5fd7ecd1d4548bdb128ac6a447f30fba85c9d79450a5Awarding agency Department of Health and Human Services · Centers for Disease Control and Prevention

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Centers for Disease Control and Prevention
Recipient company
GENETAG TECHNOLOGY, INC
Proposal award date
2019-08-01
Contract end date
2020-02-29
UEI
N78BHV2RJKJ8
Solicitation number
PA18-574
Topic code
NCIRD

Research abstract

Detecting species specific bacterial meningitis markers with iDDS probes Confidential PI Shafer David A PhD PROJECT SUMMARY Rapid and accurate molecular diagnostics assays empower physicians to make informed treatment decisions Meningitis may be caused by infection with microorganisms such as viruses gram negative GN and gram positive GP bacteria fungi or parasites Most frequently meningitis results from infections with non polio enteroviruses EV and parechoviruses PV which typically self resolve within days In contrast bacterial meningitis has a high mortality rate that approaches if not treated Meningitis patients present with similar symptoms regardless of origin thus timely diagnosis of the causative agent is paramount for patient care Patients are commonly treated with an empiric regimen of antibiotics until a definitive diagnosis can be made Nucleic acid amplification tests NAATs reduce diagnosis turnaround times by several days compared to standard culturing methods allowing shortened hospital stays appropriate use of antibiotics and a reduced financial burden to patients and the health care system Currently there are only two FDA approved NAATs for diagnosing viral and or bacterial meningitis Unfortunately these tests are only approved for use on the manufacturer s fully automated systems the costs of which are often prohibitive and may not determine the etiological agent of bacterial meningitis GeneTAG Technology Inc has developed instrument independent error preventing DNA Detection Switch iDDS probes which employ a fluorescent labeled probe and a slightly mismatched quencher labeled antiprobe In the absence of the intended target the antiprobes hybridize to the probes quenching their fluorescence and preventing off target detection Recently we developed EV and PV assays employing two iDDS probes for each target providing simultaneous color signaling and automatic confirmation of positive or negative test results We have also developed iDDS probes for GN and GP detection In the proposed studies we are interested in developing a reflex test that can be used to determine which of common bacterial species is present based on the detection of species specific genetic markers for each bacterial species Such a reflex test is important because knowing the bacterial species can guide physicians in prescribing appropriate antibiotic treatment After initial validation studies this test will be re formulated into a lyophilized format where all reagents primers and probes are included and the test would only require adding sample and molecular grade water The lyophilized test will be re evaluated with genomic DNA samples representing each bacterial test species and cerebrospinal fluid specimens Ultimately we are interested in gaining FDA approval for our lyophilized meningitis assay Delivering a high fidelity cost effective meningitis assay should positively impact meningitis diagnostics guide physicians in selecting appropriate therapy and provide a direct benefit to public health Detecting species specific bacterial meningitis markers with iDDS probes Confidential PI Shafer David A PhD PROJECT NARRATIVE Determining the etiological agent of spinal meningitis is critical for patient care Unfortunately the only FDA approved nucleic acid amplification tests for bacterial and viral meningitis require expensive instrumentation which limits point of care testing and slows diagnosis and may not identify the bacterial species involved which is key for selecting effective antibiotics Previously we developed assays for distinguishing bacterial and viral meningitis that can be used on various real time PCR instruments already present in diagnostic labs We will upgrade our test to include species specific bacterial markers so that physicians can first discern between bacterial and viral meningitis and then decide appropriate therapy in the case of bacterial meningitis

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

12 SBIR/STTR records share this UEI (2009–2022). Reported award amounts total $3,544,368. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.